About Myeloma: A Shareable Guide for Patients, Family and Friends


Do you love Patient Power? Want other cancer patients to feel empowered too? Help spread the word about Patient Power by sharing our downloadable guide. Simply save the guide to your computer, then print out a few copies and pass them out to fellow patients and doctors during your next appointment. You can also share it via email or social media. This way, people who don't know about Patient Power are now in the loop and can become a part of the Patient Power community! You, loyal Patient Power community member, are our greatest advocate, and we appreciate you! Thanks for helping us share our free, educational resources with the world!



  • Multiple myeloma is a cancer formed by malignant plasma cells in the blood. 
  • Plasma cells are typically found in the bone marrow where blood cells are created and are an important part of the immune system. When plasma cells become cancerous and grow out of control, they can produce a tumor called a plasmacytoma. If someone has more than one plasmacytoma, they have multiple myeloma. 
  • There are subtypes of myeloma, and the course of the disease can vary greatly by patient. 
  • There are now several effective medicines, used alone or in combination, that treat myeloma, and people are living longer with a better quality of life than ever before. Treatment research is accelerating, and there is growing possibility that new medicines can activate the immune system to more successfully combat this disease.
  • It is important to inquire about clinical trials to potentially access promising breakthrough therapies.


Myeloma Support

A diagnosis of multiple myeloma can be overwhelming for the entire family. Open discussion between family members, health professionals and patients can help ensure the best care. There are many resources available to find a wide range of information on the management and treatment of multiple myeloma. We encourage you to join our community and to check out our brief videos to find the most up-to-date information from leading experts about support, treatments, clinical trials, communication, financial issues and much more.

Join the Community

Myeloma Clinical Trials



About Myeloma: A Shareable Guide for Patients, Family and Friends

Email this program

Get Link

Myeloma Videos and Transcripts

What Is Multiple Myeloma? An Expert Explains

We know multiple myeloma is a blood cancer, but what it is it exactly? Dr. Robert Orlowski defines myeloma, describes the early symptoms, and discusses the diagnostic procedures.


Exciting New Agents for the Treatment of Multiple Myeloma

Dr. Paul Richardson from the Dana-Farber Cancer Institute joined Jack Aiello at our recent multiple myeloma town meeting to share his perspective on a number of agents for multiple myeloma, including monoclonal antibodies and how they work, as well as immunotherapy.


Smoldering Myeloma and MGUS: Why Watch and Wait?

Dr. Robert Orlowski from MD Anderson Cancer Center and Dr. Paul Richardson from Dana-Farber Cancer Institute, define the terms MGUS and smoldering myeloma as well as the reasoning behind the watch and wait period.


Taking Charge of Your Health: Advice From a Hematologist

Continuing with our coverage of the 2015 American Society of Hematology (ASH) meeting, Dr. Robert Hromas, hematologist at the University of Florida College of Medicine, shares advice to patients on how and why you should be taking charge of your health.


Why Bisphosphonates Are an Important Tool in Myeloma Treatment

Dr. Robert Orlowski and Dr. Paul Richardson discuss bisphosphonates related to myeloma treatment. They review the concept of bisphosphonates, including the benefits and the duration for which these therapies should be used.


When Should I Consider a Clinical Trial for Multiple Myeloma Treatment?

Hear why Dr. Robert Orlowski thinks patients should consider clinical trials at every step in their multiple myeloma treatment journey.


Can I Avoid or Postpone Stem Cell Transplant for Multiple Myeloma?

Dr. Orlowski discusses whether it makes sense for some multiple myeloma patients to avoid stem cell transplant in light of recent drug developments.


Understanding M Protein Level and MRD Testing in Myeloma

What is a good M protein level range for myeloma patients? When is MRD testing recommended? Watch now to hear expert Dr. Elisabet Manasanch explain.


In Myeloma, How Is Minimal Residual Disease (MRD) Measured?

Dr. Robert Orlowski from MD Anderson Cancer Center and Dr. Paul Richardson from Dana-Farber Cancer Institute explain minimal residual disease (MRD), how it’s measured and what the test means related to prognosis.


Showing 9 of 10 programs
Join Our Community Register for Events Read Our Latest Blog

Page last updated on May 6, 2019